摘要
目的:探究与分析依达拉奉治疗急性脑出血的临床疗效与安全性。方法:选取我院2013-03-2015-03收治的60例急性脑出血患者,采取随机数字表法分为常规治疗组与依达拉奉组,每组各30例,比较2组患者治疗前后脑水肿及脑血肿体积变化、Hs-CRP及IL-6水平变化、CSS评分情况。结果:与治疗前比较,2组治疗后7d、14d脑水肿与脑血肿体积、Hs-CRP及IL-6水平变化、CSS评分情况均明显减少(P<0.05);治疗后7d、14d,2组脑水肿与脑血肿体积比较差异无统计学意义(P>0.05),依达拉奉组Hs-CRP及IL-6水平、CSS评分较常规治疗组均减少更加显著(P<0.05)。依达拉奉组、常规治疗组的不良反应发生率为16.67%、13.33%,2组比较差异无统计学意义(P>0.05)。结论:采用依达拉奉治疗急性脑出血的临床疗效显著,改善缺损的神经功能,无明显不良反应,安全性较高,值得推广。
Objective：To explore and analyze the clinical efficacy and security of the treatment of edaravone in acute cerebral hemorrhage.Method：Selecting 60 patients with acute cerebral hemorrhage in our hospital from March 2013 to March 2015.The 60 patients were divided into regular treatment group and edaravone group by random number table method,30 cases in each group.Cerebral edema and brain hematoma volume change,Hs-CRP and IL-6,CSS grading level change before and after treatment in two groups were compared.Result：Cerebral edema and brain hematoma volume,Hs-CRP and IL-6,CSS grading levels were significant reduced in 7d,14 dafter treatment compared with levels before treatment（P〈0.05）.Cerebral edema and brain hematoma volume of edaravone group in 7d,14 dafter treatment were not deviate significantly from regular treatment group（P〉0.05）.Hs-CRP and IL-6,CSS grading levels of edaravone group were reducing significantly than regular treatment group（P〈0.05）in 7d,14 dafter treatment.Regular treatment group＇s incidence of adverse reactions was 13.33%,which have no obvious difference with edaravone group＇s incidence of adverse reactions 16.67%（P〉0.05）.Conclusion：In treating acute cerebral hemorrhage,edaravone is worth promoting for improving nerve function defect,no untoward reaction and high security.
出处
《临床急诊杂志》
CAS
2015年第7期520-522,共3页
Journal of Clinical Emergency
关键词
依达拉奉
急性脑出血
疗效
安全性
edaravone
acute cerebral hemorrhage
efficacy
security
作者简介
通信作者：曲大鹏，E-mail：he2230035@126．com
